Cargando…

Tear fluid and complement activation products in tears after ocular surgery

PURPOSE: Due to technological advancements, surgical invasiveness has been reduced. However, cataract surgery has been implicated in causing postoperative inflammation, including dry eye syndrome. The innate immune system may be involved in postoperative inflammation, and complement activation could...

Descripción completa

Detalles Bibliográficos
Autores principales: Maehara, Hiroki, Norikawa, Koki, Tanaka, Keiichiro, Kato, Yutaka, Kasai, Akihito, Omori, Tomoko, Machida, Takeshi, Sekine, Hideharu, Sekiryu, Tetsuju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355014/
https://www.ncbi.nlm.nih.gov/pubmed/37464366
http://dx.doi.org/10.1186/s12886-023-03037-6
_version_ 1785075049140584448
author Maehara, Hiroki
Norikawa, Koki
Tanaka, Keiichiro
Kato, Yutaka
Kasai, Akihito
Omori, Tomoko
Machida, Takeshi
Sekine, Hideharu
Sekiryu, Tetsuju
author_facet Maehara, Hiroki
Norikawa, Koki
Tanaka, Keiichiro
Kato, Yutaka
Kasai, Akihito
Omori, Tomoko
Machida, Takeshi
Sekine, Hideharu
Sekiryu, Tetsuju
author_sort Maehara, Hiroki
collection PubMed
description PURPOSE: Due to technological advancements, surgical invasiveness has been reduced. However, cataract surgery has been implicated in causing postoperative inflammation, including dry eye syndrome. The innate immune system may be involved in postoperative inflammation, and complement activation could potentially play a crucial role in defense against pathogens, homeostasis, and wound healing. To investigate changes in the tear film complement activation products (CAPs) and ocular surface after vitrectomy combined with cataract surgery. METHODS: Forty-three patients (23 women; median age, 69 years) were enrolled in this prospective study and underwent phacoemulsification and vitrectomy. We measured Schirmer's test (ST) and CAPs in the tears at baseline (the day before surgery), 4 days and 1 month after the surgery. Tears were collected in microtubes. The CAPs in the tear fluid were analyzed by cytometric bead array. RESULTS: The median ST (8.5 mm) at baseline increased to 16 mm at 4 days ( P < 0.001) and 10 mm at 1 month (P = 0.44). The C3a levels (1202 pg/ml) at baseline increased to 2753 pg/ml at 4 days (P < 0.001), and 1763 pg/ml at 1 month (P = 0.049). The C4a levels (476 pg/ml) at baseline increased to 880 pg/ml at 4 days (P < 0.001), and 657 pg/ml at 1 month (P = 0.013). The C5a levels (22.6 pg/ml) at baseline increased to 470.9 pg/ml at 4 days (P < 0.001), and 38.3 pg/ml at 1 month (P = 0.0048). The surgical eyes were divided into the short ST group (≦ 10 mm, n = 22) and long ST group (> 10 mm, n = 21) based on the preoperative ST values. At 1 month postoperatively, the C3a levels were 2194 pg/ml in the preoperative short ST group and 1391 pg/ml in the long ST group, with significantly higher C3a concentrations in the short ST group (P < 0.001). CONCLUSIONS: The CAPs levels in tears increased after vitrectomy combined with cataract surgery. A preoperative deficit in tear secretion might induce prolonged complement activation and delayed recovery of ocular surface parameters postoperatively.
format Online
Article
Text
id pubmed-10355014
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103550142023-07-20 Tear fluid and complement activation products in tears after ocular surgery Maehara, Hiroki Norikawa, Koki Tanaka, Keiichiro Kato, Yutaka Kasai, Akihito Omori, Tomoko Machida, Takeshi Sekine, Hideharu Sekiryu, Tetsuju BMC Ophthalmol Research PURPOSE: Due to technological advancements, surgical invasiveness has been reduced. However, cataract surgery has been implicated in causing postoperative inflammation, including dry eye syndrome. The innate immune system may be involved in postoperative inflammation, and complement activation could potentially play a crucial role in defense against pathogens, homeostasis, and wound healing. To investigate changes in the tear film complement activation products (CAPs) and ocular surface after vitrectomy combined with cataract surgery. METHODS: Forty-three patients (23 women; median age, 69 years) were enrolled in this prospective study and underwent phacoemulsification and vitrectomy. We measured Schirmer's test (ST) and CAPs in the tears at baseline (the day before surgery), 4 days and 1 month after the surgery. Tears were collected in microtubes. The CAPs in the tear fluid were analyzed by cytometric bead array. RESULTS: The median ST (8.5 mm) at baseline increased to 16 mm at 4 days ( P < 0.001) and 10 mm at 1 month (P = 0.44). The C3a levels (1202 pg/ml) at baseline increased to 2753 pg/ml at 4 days (P < 0.001), and 1763 pg/ml at 1 month (P = 0.049). The C4a levels (476 pg/ml) at baseline increased to 880 pg/ml at 4 days (P < 0.001), and 657 pg/ml at 1 month (P = 0.013). The C5a levels (22.6 pg/ml) at baseline increased to 470.9 pg/ml at 4 days (P < 0.001), and 38.3 pg/ml at 1 month (P = 0.0048). The surgical eyes were divided into the short ST group (≦ 10 mm, n = 22) and long ST group (> 10 mm, n = 21) based on the preoperative ST values. At 1 month postoperatively, the C3a levels were 2194 pg/ml in the preoperative short ST group and 1391 pg/ml in the long ST group, with significantly higher C3a concentrations in the short ST group (P < 0.001). CONCLUSIONS: The CAPs levels in tears increased after vitrectomy combined with cataract surgery. A preoperative deficit in tear secretion might induce prolonged complement activation and delayed recovery of ocular surface parameters postoperatively. BioMed Central 2023-07-18 /pmc/articles/PMC10355014/ /pubmed/37464366 http://dx.doi.org/10.1186/s12886-023-03037-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Maehara, Hiroki
Norikawa, Koki
Tanaka, Keiichiro
Kato, Yutaka
Kasai, Akihito
Omori, Tomoko
Machida, Takeshi
Sekine, Hideharu
Sekiryu, Tetsuju
Tear fluid and complement activation products in tears after ocular surgery
title Tear fluid and complement activation products in tears after ocular surgery
title_full Tear fluid and complement activation products in tears after ocular surgery
title_fullStr Tear fluid and complement activation products in tears after ocular surgery
title_full_unstemmed Tear fluid and complement activation products in tears after ocular surgery
title_short Tear fluid and complement activation products in tears after ocular surgery
title_sort tear fluid and complement activation products in tears after ocular surgery
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355014/
https://www.ncbi.nlm.nih.gov/pubmed/37464366
http://dx.doi.org/10.1186/s12886-023-03037-6
work_keys_str_mv AT maeharahiroki tearfluidandcomplementactivationproductsintearsafterocularsurgery
AT norikawakoki tearfluidandcomplementactivationproductsintearsafterocularsurgery
AT tanakakeiichiro tearfluidandcomplementactivationproductsintearsafterocularsurgery
AT katoyutaka tearfluidandcomplementactivationproductsintearsafterocularsurgery
AT kasaiakihito tearfluidandcomplementactivationproductsintearsafterocularsurgery
AT omoritomoko tearfluidandcomplementactivationproductsintearsafterocularsurgery
AT machidatakeshi tearfluidandcomplementactivationproductsintearsafterocularsurgery
AT sekinehideharu tearfluidandcomplementactivationproductsintearsafterocularsurgery
AT sekiryutetsuju tearfluidandcomplementactivationproductsintearsafterocularsurgery